Spectrum's Rolontis meets in Phase III for chemotherapy-induced neutropenia

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) reported top-line data from the Phase III ADVANCE trial in 406 patients with early stage breast cancer who received docetaxel

Read the full 248 word article

User Sign In